About
Stefan Teipel is a full professor and specialist in psychiatry and psychotherapy at the Clinic for Psychosomatic Medicine and Psychotherapy and head of the Section for Clinical Dementia Research at the University Medical Center Rostock (since 2013). He is also deputy speaker of the German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald (since 2009).
His research focuses on the development of diagnostic and treatment approaches for neurodegenerative dementias from experimental to health care settings, as well as the development and implementation of digital assistive devices for people with dementia. The active involvement of people with dementia and their caregivers in research using participatory research methods has become an increasing focus in recent years. Stefan Teipel has received national and European research funding, and is advisory board member in national and international projects, including the Independent Data Monitoring Committee for ENVISION 221AD305 Study (Biogen), Member of the Department Individual and Societal Aging of the Interdisciplinary Faculty, University of Rostock, Co-Head of the Neuroimaging Section of the German Society of Biological Psychiatry, and Advisory Board Member of the Alzheimer Forschung Initiative (AFI) e. V., and Senior Associate Editor of Alzheimer’s & Dementia DADM.
Declaration of Interests
Strategic Advisory Roles
Duration | Company | Position/Meeting |
---|---|---|
05/2022 – ongoing | Biogen MA Inc. | Consultant Data Safety Monitoring Board |
02/2022 – 02/2022 | Biogen GmbH | Consultant Advisory Board “Antibodies from an interdisciplinary perspective” |
01/2022 – 01/2022 | Roche Pharma AG | Consultant Advisory Board |
12/2021 – 12/2021 | Biogen GmbH | Consultant 2nd Brain Trust Meeting |
11/2021 – 11/2021 | Eisai Inc. | Consultant Eisai Global Medical Affairs Advisory Board |
11/2021 – 11/2021 | Biogen GmbH | Consultant Alzheimer Round Table Mecklenburg-Western Pomerania |
09/2021 – 09/2021 | Roche Pharma AG | Consultant Alzheimer Medical Advisory Board |
07/2021 – 07/2021 | Biogen GmbH | Consultant Brain Trust Kick off Meeting |
05/2021 – 05/2021 | Biogen GmbH | Consultant Advisory Board |
04/2021 – 04/2021 | Grifols Deutschland GmbH | Consultant German Alzheimer’s disease Expert Panel |
03/2021 – 03/2021 | Roche Pharma AG | Consultant National Alzheimer Advisory Board |
01/2021 – 01/2021 | Dr. Willmar Schwabe GmbH & Co. KG | Speaker Lecture at the online Expert Discussion “MCI” |
09/2020 – 09/2020 | Biogen GmbH | Consultant AD Board MCI-Ad Case Finding in Primary Care |
04/2020 – 04/2020 | Biogen GmbH | Consultant Virtual Alzheimer Advisory Session I |
04/2020 – 04/2020 | Biogen GmbH | Consultant Virtual AAT-AD PD Focus Meeting |
02/2020 – 02/2020 | Philips GmbH Market DACH |
Speaker Symposium “Update Dementias” |
09/2019 – 09/2019 | Roche Pharma AG | Consultant Advisory Board |
09/2019 – 09/2019 | Roche Pharma AG | Speaker Roche Symposium “DNG” |
08/2019 – 08/2019 | MSD Sharp & Dohme GmbH | Speaker Symposium “Diabetes and Dementia” |
Financial Interests
Date | Company | Role |
---|---|---|
04/2023 – 04/2023 | EISAI GmbH | Honorarium for oral presentation at Auguste Symposium in Berlin, 22.04.2023 |
Date | Company | Product Name | Therapeutic Indication (Country) |
---|---|---|---|
04/2021 – ongoing | Roche Pharma AG | Gantenerumab | Alzheimer Disease (Germany) |
08/2019 – 12/2022 | Boehringer Ingelheim Pharma GmbH & Co. KG | Methodological Study: Development of a software application for speech analysis in patients with AD | N/A |
10/2018 – ongoing | Roche Pharma AG | Gantenerumab | Alzheimer Disease (Germany) |
01/2017 – 12/2019 | Piramal Imaging Ltd. | NeuraCeqTM | Amyloid PET Diagnostic (UK) |
11/2014 – 12/2019 | H. Lundbeck A/S | Lu AE58054 | Alzheimer Disease (Denmark) |
Investigator
Duration | Company | Product Name | Therapeutic Indication |
---|---|---|---|
11/2019 – ongoing | Fujifilm Toyama Chemical Ltd, NL | T-817MA | Alzheimer Disease |